RxDoctor Payments Data

Karen Conn

Family · Huntsville, ALNPI 1558015511

Payments from drug & device makers

$3,066in general payments, 2019–2025

Across 184 payments — averaging $16.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$679
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$537
  • Regeneron Healthcare Solutions, Inc.$426
  • Gilead$280
  • Madrigal Pharmaceuticals$270
  • Takeda Pharmaceuticals U.S.A., Inc.$232
  • plus $641 from 9 others

What the payments were for

  • Food & beverage$2,96697%
  • Gifts$1003%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,066 in reported general payments places this provider in the 80th percentile of 3,415 family providers in Alabama.

See all family providers in Alabama

Medicare billing

Part B allowed, 2024
$52,509
Medicare patients
390
Services billed
537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide61$56,486
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates264$16,900
SutabSod Sulf/Pot Chloride/Mag Sulf20$3,194
Omeprazole177$3,131
Lactulose56$2,367
SuflavePeg 3350/Sod Sulf,chlr/Pot/Mag19$2,311
ConstuloseLactulose43$1,650
Balsalazide Disodium13$678
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl35$629
Procto-Med HcHydrocortisone27$552
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl27$477
Sucralfate12$464
Ursodiol11$433
Famotidine19$365
Hydrocortisone27$344

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$679$56,48661 claims
Braintree Laboratories, Inc.Sutab, Suflave$53$5,50539 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 3,415 family providers in Alabama.

Other family in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →